MaxCyte to Buy Akron Bio for $151.8 Million

• MaxCyte will acquire cell therapy materials supplier Akron Bio from Arcline affiliates for $151.8 million, with closing expected before year-end 2026.
• Closing consideration includes $105 million in cash and 20,639,733 common shares valued at approximately $26.8 million.
• Guaranteed deferred payments total $20 million, payable in $10 million installments on the first business day of January 2028 and January 2029.
• Akron projects 2026 revenue of approximately $28 million and EBITDA of $7 million–$8 million; the acquisition is expected to nearly double revenue.
• A new $75 million MidCap Financial credit facility, together with existing cash, is expected to fund the combined company through profitability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MaxCyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100600PRIMZONEFULLFEED9874252) on November 10, 2026, and is solely responsible for the information contained therein.